Enliven Therapeutics Inc (NASDAQ:ELVN)’s traded shares stood at 0.35 million during the last session, with the company’s beta value hitting 1.09. At the close of trading, the stock’s price was $27.53, to imply an increase of 7.92% or $2.02 in intraday trading. The ELVN share’s 52-week high remains $27.67, putting it -0.51% down since that peak but still an impressive 64.4% since price per share fell to its 52-week low of $9.80. The company has a valuation of $1.30B, with an average of 0.49 million shares in intraday trading volume over the past 10 days and average of 239.55K shares over the past 3 months.
Enliven Therapeutics Inc (NASDAQ:ELVN) trade information
After registering a 7.92% upside in the last session, Enliven Therapeutics Inc (ELVN) has traded red over the past five days. The 5-day price performance for the stock is 14.09%, and 25.65% over 30 days. With these gigs, the year-to-date price performance is 98.92%. Short interest in Enliven Therapeutics Inc (NASDAQ:ELVN) saw shorts transact 5.53 million shares and set a 41.69 days time to cover.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The extremes give us $32 and $39 for target low and target high price respectively. As such, ELVN has been trading -41.66% off suggested target high and -16.24% from its likely low.
Enliven Therapeutics Inc (ELVN) estimates and forecasts
Looking at statistics comparing Enliven Therapeutics Inc share performance against respective industry, we note that the company has underperformed competitors. Enliven Therapeutics Inc (ELVN) shares are 41.91% up over the last 6 months, with its year-to-date growth rate lower than industry average at 1.49% against 19.40%. Revenue is forecast to grow 2.00% this quarter before falling -12.80% for the next one.
ELVN Dividends
Enliven Therapeutics Inc has its next earnings report out on 2024-Nov-07. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Enliven Therapeutics Inc (NASDAQ:ELVN)’s Major holders
Enliven Therapeutics Inc insiders hold 6.61% of total outstanding shares, with institutional holders owning 102.85% of the shares at 110.13% float percentage. In total, 102.85% institutions holds shares in the company.
